{"gene":"GLO1","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":2010,"finding":"GLO1 encodes glyoxalase 1, a glutathione-dependent enzyme that detoxifies methylglyoxal (MG), a cytotoxic byproduct of glycolysis. siRNA knockdown of GLO1 sensitized cancer cells to methylglyoxal cytotoxicity, and cells with GLO1 amplification were more sensitive to GLO1 inhibition by bromobenzylglutathione cyclopentyl diester (BBGC), establishing GLO1 as a functional detoxification enzyme required for cell survival under glycolytic stress.","method":"RNAi knockdown, pharmacological inhibition, cell accumulation and apoptosis assays","journal":"Genes, chromosomes & cancer","confidence":"High","confidence_rationale":"Tier 2 — clean KD/KO with defined cellular phenotype, replicated across multiple cancer cell lines","pmids":["20544845"],"is_preprint":false},{"year":2010,"finding":"GLO1 knockdown in human metastatic melanoma cells increased methylglyoxal-mediated protein adduction; the major methylglyoxal-adducted protein was identified as heat shock protein 27 (Hsp27/HSPB1) by 2D proteomics and mass spectrometry, identifying Hsp27 as a key cellular substrate of MG when GLO1 is absent.","method":"siRNA knockdown, immunodetection with anti-argpyrimidine antibody, 2D proteomics, mass spectrometry","journal":"Melanoma research","confidence":"Medium","confidence_rationale":"Tier 2 — MS identification of adducted substrate, single lab with orthogonal methods","pmids":["20093988"],"is_preprint":false},{"year":2014,"finding":"The GLO1 C332 (Ala111) variant reduces glyoxalase enzymatic activity in leukocytes and post-mortem brain tissue without altering GLO1 protein levels, and is associated with increased AGE formation; a strong negative correlation between glyoxalase activity and AGE levels was demonstrated, establishing a functional consequence of this coding variant on the GLO1-AGE axis.","method":"Enzymatic activity assays in leukocytes and post-mortem brain tissue, AGE quantification, genotype-stratified analysis","journal":"Journal of psychiatric research","confidence":"Medium","confidence_rationale":"Tier 2 — enzymatic activity measured in human tissue with functional correlation, single lab","pmids":["25201284"],"is_preprint":false},{"year":2015,"finding":"Neuronal-specific overexpression of Glo1 (via Synapsin 1-Cre) is sufficient to increase anxiety-like behavior in mice, and direct microinjection of methylglyoxal (MG) into the basolateral amygdala (BLA) reduced anxiety-like behavior, demonstrating that GLO1 regulates anxiety through neuronal MG levels acting in the amygdala.","method":"Conditional transgenic overexpression (ROSA26 knock-in x Syn-CRE), stereotaxic microinjection, behavioral assays","journal":"Behavioural brain research","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific genetic manipulation and anatomically targeted pharmacology with defined behavioral phenotype","pmids":["26711908"],"is_preprint":false},{"year":2016,"finding":"When Glo1 levels were decreased in embryonic mouse cortical neural precursor cells (NPCs), this caused premature neurogenesis and NPC depletion embryonically and long-term alterations in cortical neurons postnatally; increased circulating maternal methylglyoxal caused similar changes, establishing that the Glo1-MG pathway regulates neural stem cell pool maintenance.","method":"Glo1 loss-of-function in embryonic NPCs, maternal MG exposure model, cortical precursor analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacological perturbation with defined cellular phenotype, orthogonal approaches","pmids":["27760310"],"is_preprint":false},{"year":2016,"finding":"GLO1 knockdown (shRNA) in MCF-7 cancer cells significantly reduced tumor-associated properties such as migration and proliferation; GLO1 overexpression in HEK293 cells conferred resistance to hypoxia-induced growth inhibition, indicating that GLO1 activity maintains malignant cell properties and supports growth under hypoxic stress.","method":"shRNA knockdown, overexpression, cell migration and proliferation assays, hypoxia experiments","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional genetic manipulation with multiple cellular phenotype readouts, single lab","pmids":["27999356"],"is_preprint":false},{"year":2014,"finding":"GLO1 is translocated into the nucleus to a greater extent in progressive (QRsP-11) compared to regressive (QR-32) murine fibrosarcoma cells; this nuclear translocation is reversed by the MEK inhibitor U0126, and GLO1 siRNA inhibits cell proliferation and migration, placing GLO1 nuclear localization downstream of MEK/ERK signaling.","method":"2D proteomics, MS, MEK inhibitor treatment, siRNA knockdown, subcellular fractionation/immunofluorescence","journal":"Electrophoresis","confidence":"Medium","confidence_rationale":"Tier 3 — localization experiment with functional follow-up, single lab","pmids":["24532130"],"is_preprint":false},{"year":2013,"finding":"GLO1 knockdown via siRNA in L6 myoblasts under hyperglycemic conditions caused accumulation of methylglyoxal and augmented GLUT4 levels at the cell surface at least in part through reduction of GLUT4 internalization, resulting in increased glucose uptake; NAC (antioxidant/MG scavenger) prevented MG-induced GLUT4 translocation, linking GLO1 to regulation of glucose transporter trafficking.","method":"siRNA knockdown, GLUT4 surface expression assay (myc-tagged GLUT4), pharmacological rescue","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — KD with specific cellular phenotype (GLUT4 trafficking), pharmacological confirmation, single lab","pmids":["23717693"],"is_preprint":false},{"year":2018,"finding":"GLO1 inhibition in glioblastoma (GBM) cell lines and in an orthotopic xenograft model increased levels of the DNA-AGE CEdG (N2-1-(carboxyethyl)-2'-deoxyguanosine), substantially elevated RAGE expression, and induced apoptosis; shRNA targeting of GLO1 similarly increased CEdG and RAGE expression, demonstrating that GLO1 protects GBM cells from MG-induced DNA glycation and RAGE-mediated apoptosis.","method":"Pharmacological GLO1 inhibition, shRNA knockdown, CEdG biomarker quantification, RAGE expression analysis, orthotopic xenograft model","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 2 — orthogonal genetic and pharmacological approaches, in vitro and in vivo validation","pmids":["29385725"],"is_preprint":false},{"year":2018,"finding":"MMSET I (a short isoform of the t(4;14) myeloma oncoprotein) binds upstream of the GLO1 transcription start site (demonstrated by ChIP-qPCR) and increases GLO1 expression; ectopic overexpression of GLO1 significantly rescued KMS11 myeloma cells from MMSET I knockdown-induced apoptosis and glycolysis inhibition, placing GLO1 as a functional downstream effector of MMSET I.","method":"ChIP-qPCR, gene expression array, knockdown and overexpression rescue experiments, apoptosis assays","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrates direct binding at GLO1 locus, rescue experiment confirms functional downstream relationship","pmids":["30470837"],"is_preprint":false},{"year":2015,"finding":"Monacolin K reduces GLO1 expression in U937 AML cells through inhibition of the Ras/Raf/ERK/NF-κB and Ras/PI3K/Akt/NF-κB pathways; use of specific pathway inhibitors (U0126, LY294002, JSH-23) confirmed that NF-κB downstream of Ras/ERK and Ras/Akt regulates GLO1 expression and that GLO1 downregulation mediates monacolin K-induced apoptosis.","method":"Pharmacological inhibitors, pathway activity assays, apoptosis analysis","journal":"Journal of agricultural and food chemistry","confidence":"Medium","confidence_rationale":"Tier 3 — pathway inhibitor approach identifies upstream regulators of GLO1, single lab","pmids":["25569448"],"is_preprint":false},{"year":2019,"finding":"Reduction of GLO1 in basilar artery smooth muscle cells (BASMCs) promoted, while overexpression prevented, angiotensin II-induced cell proliferation and cell cycle transition; these effects were mediated through PI3K/AKT/CDK2 cascade activation; in vivo, AAV-mediated GLO1 overexpression improved cerebrovascular remodeling in hypertensive mice, placing GLO1 as a negative regulator of the PI3K/AKT/CDK2 proliferative pathway in vascular smooth muscle.","method":"Knockdown and overexpression in BASMCs, signaling pathway analysis, AAV gene delivery in mouse model, histological analysis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — bidirectional manipulation in vitro and in vivo with mechanistic pathway identification","pmids":["31420161"],"is_preprint":false},{"year":2020,"finding":"CRISPR/Cas9-based GLO1 deletion from A375 melanoma cells upregulated TXNIP (thioredoxin-interacting protein) as the most pronounced expression change; GLO1 deletion also altered glucose metabolism (downregulation of GLUT1, GFAT1, GFAT2, LDHA; depletion of glucose-6-phosphate and UDP-N-acetylglucosamine) and modulated immune checkpoint gene expression (PDL1). Treatment with MG or a GLO1 inhibitor mimicked the GLO1 KO effect on TXNIP, indicating GLO1 controls TXNIP expression via MG regulation.","method":"CRISPR/Cas9 knockout, NanoString gene expression profiling, RT-qPCR, immunoblot, metabolite analysis, pharmacological mimicry","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 1–2 — CRISPR KO with multi-omic validation, pharmacological mimicry, replicated in second cell line","pmids":["33360689"],"is_preprint":false},{"year":2025,"finding":"Itaconate promotes proteasomal degradation of GLO1 via Cys139 alkylation in macrophages, leading to MGO and AGE accumulation and exacerbating inflammatory responses; elevated itaconate in sepsis patients correlated with reduced GLO1 in PBMCs, and myeloid-specific AGER knockout mice showed reduced inflammation and improved survival in sepsis, linking itaconate-driven GLO1 degradation to the inflammatory AGE/RAGE axis.","method":"Proteasomal degradation assay, site-directed mutagenesis (Cys139), patient PBMC analysis, conditional knockout mouse model of sepsis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1–2 — mechanism identified by mutagenesis of specific residue, validated in vivo and in patient samples","pmids":["39787788"],"is_preprint":false},{"year":2025,"finding":"Crotonylation of GLO1 at lysine 157 (K157) was found at higher levels in saphenous vein (SV) compared to internal thoracic artery (ITA) grafts; site-specific GLO1 crotonylation decreased enzymatic activity and was associated with elevated methylglyoxal accumulation and increased oxidative stress. Overexpression of HDAC1/HDAC3 reversed GLO1 crotonylation and restored activity. CBP inhibition reversed SV oxidative stress.","method":"PTM proteomics, site-mutation experiments in HEK293 cells, HDAC overexpression, ex vivo cultured ITA/SV tissue, pharmacological inhibition","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 1 — site-specific mutagenesis combined with enzymatic activity assays and in vivo tissue validation","pmids":["40138913"],"is_preprint":false},{"year":2024,"finding":"SIRT2 knockdown attenuated GLO1 protein by ~28% and activity by ~42% in human myotubes; NAMPT knockdown also reduced GLO1 protein, activity, and transcripts; neither manipulation altered GLO1 acetylation status, suggesting NAD+-dependent regulation of GLO1 expression and activity independent of direct acetylation.","method":"siRNA knockdown of SIRT2 and NAMPT, GLO1 activity assays, acetylation immunoprecipitation, NR/NMN supplementation","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 — specific KD of regulatory enzymes with enzymatic activity readout, single lab","pmids":["39142179"],"is_preprint":false},{"year":2022,"finding":"lncRNA RP11-162G10.5 recruits the transcription factor YBX1 to the GLO1 promoter, activating GLO1 transcription in breast cancer; this was demonstrated by ChIP and rescue experiments showing that YBX1 or GLO1 knockdown reversed RP11-162G10.5-driven tumor promotion.","method":"ChIP, luciferase reporter assay, knockdown and rescue experiments, in vivo xenograft","journal":"Cellular oncology (Dordrecht, Netherlands)","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP shows direct promoter recruitment, functional rescue confirms pathway","pmids":["36576700"],"is_preprint":false},{"year":2024,"finding":"CircMAN1A2_009 interacts with YBX1, facilitating phosphorylation of YBX1 at serine 102 (p-YBX1-S102) and promoting YBX1 nuclear localization via sequence 245–251, which in turn increases GLO1 promoter activity and GLO1 expression in cervical adenocarcinoma cells.","method":"Co-immunoprecipitation, luciferase reporter assay, knockdown/overexpression, nuclear localization imaging","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 3 — mechanistic dissection of circRNA-protein-promoter axis with functional validation, single lab","pmids":["39038813"],"is_preprint":false},{"year":2025,"finding":"In TXNIP-deficient patient-derived primary myoblasts and fibroblasts, NRF2 activation was associated with upregulation of GLO1; increased GLO1 led to elevated D-lactate production (downstream product of MG detoxification), suggesting that TXNIP deficiency causes increased glycolytic MGO flux that activates NRF2, which in turn induces GLO1 expression.","method":"Patient-derived primary cells, D-lactate quantification, NRF2 pathway analysis, GLO1 expression/activity measurement","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 — patient-derived cells with metabolite readouts establish pathway connectivity, single study","pmids":["40721014"],"is_preprint":false},{"year":2025,"finding":"In a yeast model (ortholog study), absence of Glo1 greatly elevated MG-induced genome-wide mutagenesis in single-stranded DNA; MG mutagenesis occurred via a guanine-centered strand slippage and mispairing mechanism requiring the translesion polymerase Rev1. This establishes that GLO1/Glo1 protects genome integrity from MG-induced mutagenesis via a defined Rev1-dependent mechanism.","method":"Yeast Glo1 deletion, whole-genome mutation spectrum analysis, Rev1 deletion epistasis, aminoguanidine quencher rescue","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis (glo1 and rev1 deletions) with genome-wide mutagenesis readout, ortholog study in yeast","pmids":["bio_10.1101_2025.03.18.643935"],"is_preprint":true},{"year":2026,"finding":"Glo1 is enriched in glioma stem cell (GSC) populations defined by stemness markers; genetic knockdown or pharmacological inhibition of Glo1 reduced GSC viability and tumor growth and prolonged survival in PDX and IUE-GBM mouse models. Mechanistically, Glo1 modulation disrupted transcriptional programs associated with GSC maintenance by modulating Sox2 activity.","method":"Single-cell transcriptomics, genetic overexpression/knockdown, pharmacological inhibition, PDX and IUE preclinical GBM models, Sox2 activity analysis","journal":"Neuro-oncology","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological approaches in multiple in vivo models with mechanistic pathway identification","pmids":["42011505"],"is_preprint":false},{"year":2025,"finding":"GLO1 promotes lymph node metastasis in breast cancer partly by inhibiting proteasomal degradation of glutathione synthetase (GSS), thereby maintaining intracellular glutathione (GSH) and reactive oxygen species (ROS) balance, and by promoting lymphatic angiogenesis.","method":"Single-cell RNA sequencing, multi-omics, experimental validation (proteasome inhibition, GSH/ROS measurement), in vitro and in vivo metastasis assays","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 3 — mechanistic follow-up with GSS proteasomal degradation assay, single lab","pmids":["40492378"],"is_preprint":false},{"year":2024,"finding":"Butyrate (NaB) inhibits the JAK2/STAT3/Nrf2/Glo1 pathway in castration-resistant prostate cancer cells (DU145); co-treatment with the STAT3 activator Colivelin reversed NaB effects on GLO1 expression, MG-H1 production, and cell viability; overexpression of STAT3 or GLO1 reduced NaB-induced cell death, placing GLO1 downstream of JAK2/STAT3/Nrf2 as a survival effector.","method":"Pharmacological inhibition/activation, overexpression rescue, pathway protein analysis, MGO adduct quantification","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 3 — pathway epistasis via rescue experiments, single lab","pmids":["38577936"],"is_preprint":false}],"current_model":"GLO1 encodes glyoxalase 1, a glutathione-dependent enzyme that detoxifies the reactive glycolytic byproduct methylglyoxal (MG) by converting it to D-lactate, thereby preventing MG-derived protein/DNA glycation (AGE formation) and protecting against cytotoxicity; its activity is regulated at multiple levels including transcriptional activation by MMSET I and YBX1-containing complexes, post-translational crotonylation at K157 (reducing activity), itaconate-driven proteasomal degradation via Cys139, and NAD+-dependent regulation by SIRT2/NAMPT, while GLO1-controlled MG levels in neurons modulate GABA-A receptor activity and anxiety-like behavior through the basolateral amygdala, and in cancer cells GLO1 promotes survival, proliferation, and metastasis by regulating TXNIP, GSS stability, Sox2-driven stemness programs, and the PI3K/AKT/CDK2 proliferative axis."},"narrative":{"teleology":[{"year":2010,"claim":"Establishing GLO1 as a functional methylglyoxal detoxification enzyme required for cancer cell survival resolved the question of whether GLO1 is merely a metabolic housekeeping gene or an actionable survival factor under glycolytic stress.","evidence":"siRNA knockdown and pharmacological inhibition with BBGC across multiple cancer cell lines with apoptosis readout","pmids":["20544845"],"confidence":"High","gaps":["Catalytic mechanism not structurally resolved in this study","Relative contribution of GLO1 vs. GLO2 to MG clearance not addressed","In vivo tumor dependency not tested"]},{"year":2010,"claim":"Identifying Hsp27 as a major MG-adducted protein upon GLO1 loss revealed a specific downstream target of unchecked methylglyoxal toxicity.","evidence":"2D proteomics and mass spectrometry of anti-argpyrimidine-reactive proteins in GLO1-knockdown melanoma cells","pmids":["20093988"],"confidence":"Medium","gaps":["Only one adducted substrate identified; global adductome not mapped","Functional consequence of Hsp27 glycation not determined","Single cell line"]},{"year":2013,"claim":"Demonstrating that GLO1 knockdown increases surface GLUT4 via reduced internalization under hyperglycemia linked GLO1-MG metabolism to glucose transporter trafficking, extending its role beyond detoxification to metabolic regulation.","evidence":"siRNA knockdown in L6 myoblasts with myc-tagged GLUT4 surface assay and NAC rescue","pmids":["23717693"],"confidence":"Medium","gaps":["Direct MG target mediating GLUT4 retention unknown","Not replicated in primary muscle cells or in vivo","Mechanism of endocytosis inhibition by MG not resolved"]},{"year":2014,"claim":"The Ala111 coding variant (C332) was shown to reduce GLO1 enzymatic activity without altering protein levels and to correlate with increased AGE formation in human tissues, establishing a genotype–activity–glycation axis relevant to human disease.","evidence":"Enzymatic activity assays in human leukocytes and post-mortem brain, genotype-stratified AGE quantification","pmids":["25201284"],"confidence":"Medium","gaps":["Structural basis for reduced activity not determined","Causal link to specific neuropsychiatric or metabolic disease not established in this study","Single cohort"]},{"year":2014,"claim":"Observation that GLO1 undergoes MEK/ERK-dependent nuclear translocation in aggressive tumor cells raised the possibility of non-cytosolic functions beyond canonical MG detoxification.","evidence":"Subcellular fractionation, immunofluorescence, MEK inhibitor (U0126) treatment in murine fibrosarcoma lines","pmids":["24532130"],"confidence":"Medium","gaps":["Nuclear function of GLO1 undefined","No nuclear substrate or binding partner identified","Mechanism of translocation not resolved"]},{"year":2015,"claim":"Mapping GLO1 expression downstream of Ras/ERK and Ras/PI3K/Akt via NF-κB placed GLO1 transcription under oncogenic signaling control, explaining its frequent upregulation in cancer.","evidence":"Pathway-specific inhibitors (U0126, LY294002, JSH-23) in AML cells with GLO1 expression readout","pmids":["25569448"],"confidence":"Medium","gaps":["Direct NF-κB binding to GLO1 promoter not shown by ChIP","Contribution of other transcription factors not excluded","Single cell line"]},{"year":2015,"claim":"Neuronal-specific Glo1 overexpression and direct amygdala MG injection demonstrated that GLO1 modulates anxiety-like behavior through MG levels in the basolateral amygdala, establishing a neuroactive role for a metabolic enzyme.","evidence":"Conditional transgenic Glo1 overexpression (ROSA26 × Syn-Cre), stereotaxic MG microinjection, elevated plus maze and open field tests","pmids":["26711908"],"confidence":"High","gaps":["Molecular target of MG in neurons (e.g., GABA-A receptor modulation) not directly shown in this study","Chronic vs. acute MG effects not distinguished","Human relevance of GLO1-anxiety link not established"]},{"year":2016,"claim":"Glo1 loss-of-function in embryonic neural precursor cells caused premature neurogenesis and NPC depletion, extending GLO1's biological role to neural stem cell pool maintenance during cortical development.","evidence":"Glo1 knockdown in embryonic cortical NPCs and maternal MG exposure model with postnatal cortical neuron analysis","pmids":["27760310"],"confidence":"High","gaps":["Downstream MG target driving premature differentiation not identified","Whether effect is MG-dose-dependent or threshold-based unknown","Long-term behavioral consequence of NPC depletion not tested"]},{"year":2018,"claim":"GLO1 inhibition in glioblastoma cells increased the DNA-AGE CEdG and RAGE expression, triggering apoptosis, which demonstrated that GLO1 protects tumor cells from MG-induced DNA glycation and the consequent RAGE-mediated death cascade.","evidence":"Pharmacological and shRNA GLO1 inhibition in GBM cells and orthotopic xenografts with CEdG and RAGE quantification","pmids":["29385725"],"confidence":"High","gaps":["Whether CEdG is the causative lesion or a biomarker not resolved","RAGE-independent apoptotic contributions not excluded","DNA repair response to CEdG not characterized"]},{"year":2018,"claim":"ChIP-qPCR showing MMSET I binding upstream of GLO1 and functional rescue by GLO1 overexpression identified GLO1 as a direct transcriptional target and effector of MMSET I in myeloma.","evidence":"ChIP-qPCR at GLO1 locus, MMSET I knockdown with GLO1 overexpression rescue in KMS11 myeloma cells","pmids":["30470837"],"confidence":"High","gaps":["Whether MMSET I histone methylation activity is required for GLO1 induction not tested","Contribution of other MMSET I targets to the phenotype not excluded"]},{"year":2019,"claim":"Bidirectional manipulation of GLO1 in vascular smooth muscle cells revealed it as a negative regulator of angiotensin II–driven proliferation via PI3K/AKT/CDK2, and AAV-mediated Glo1 overexpression ameliorated cerebrovascular remodeling in hypertensive mice.","evidence":"GLO1 knockdown/overexpression in BASMCs, signaling analysis, AAV delivery in hypertensive mouse model","pmids":["31420161"],"confidence":"High","gaps":["Whether MG directly activates PI3K or acts via AGE/RAGE not resolved","Specificity to vascular vs. other smooth muscle not tested"]},{"year":2020,"claim":"CRISPR knockout of GLO1 in melanoma identified TXNIP as the most upregulated gene and showed broad metabolic reprogramming (GLUT1, LDHA, hexosamine pathway), establishing GLO1 as a regulator of metabolic gene networks via MG.","evidence":"CRISPR/Cas9 GLO1 KO in A375 cells, NanoString profiling, metabolite analysis, pharmacological MG mimicry","pmids":["33360689"],"confidence":"High","gaps":["Mechanism linking MG to TXNIP transcriptional induction not defined","Immune checkpoint (PDL1) regulation not causally dissected","In vivo consequence of TXNIP upregulation not tested"]},{"year":2022,"claim":"Identification of YBX1 as a GLO1 promoter-binding transcription factor recruited by lncRNA RP11-162G10.5 established a noncoding RNA–transcription factor axis controlling GLO1 expression in breast cancer.","evidence":"ChIP, luciferase reporter, knockdown/rescue experiments, xenograft validation","pmids":["36576700"],"confidence":"Medium","gaps":["Whether YBX1 is sufficient without the lncRNA not tested","Broader applicability beyond breast cancer not established"]},{"year":2024,"claim":"Placing GLO1 downstream of the JAK2/STAT3/Nrf2 pathway in castration-resistant prostate cancer provided an additional transcriptional regulatory axis and showed GLO1 as a survival effector in therapy-resistant contexts.","evidence":"Butyrate treatment, STAT3 activator rescue, GLO1 overexpression rescue in DU145 cells","pmids":["38577936"],"confidence":"Medium","gaps":["Direct Nrf2 binding to GLO1 promoter not confirmed by ChIP","Single cell line","In vivo relevance not tested"]},{"year":2024,"claim":"SIRT2 and NAMPT knockdown reduced GLO1 protein and activity without altering GLO1 acetylation, revealing NAD+-dependent but acetylation-independent regulation of GLO1 in muscle cells.","evidence":"siRNA knockdown of SIRT2 and NAMPT in human myotubes, GLO1 activity assays, acetylation immunoprecipitation","pmids":["39142179"],"confidence":"Medium","gaps":["Mechanism by which NAD+ supports GLO1 expression/stability undefined","Whether SIRT2 acts transcriptionally or post-translationally unclear","Single tissue type"]},{"year":2025,"claim":"Itaconate was shown to alkylate GLO1 at Cys139 and trigger its proteasomal degradation in macrophages, linking innate immune metabolite signaling to methylglyoxal accumulation and AGE/RAGE-driven inflammation in sepsis.","evidence":"Site-directed mutagenesis of Cys139, proteasomal degradation assays, patient PBMC analysis, myeloid-specific AGER knockout mice in sepsis model","pmids":["39787788"],"confidence":"High","gaps":["E3 ubiquitin ligase mediating degradation not identified","Whether other cysteine modifications similarly destabilize GLO1 not tested","Therapeutic potential of blocking Cys139 alkylation not explored"]},{"year":2025,"claim":"Discovery that crotonylation at K157 inhibits GLO1 enzymatic activity, reversed by HDAC1/HDAC3, identified a new post-translational regulatory switch relevant to vascular oxidative stress.","evidence":"PTM proteomics, site-directed mutagenesis in HEK293 cells, HDAC overexpression, ex vivo ITA/SV tissue analysis","pmids":["40138913"],"confidence":"High","gaps":["Acetyltransferase responsible for K157 crotonylation not definitively identified beyond CBP correlation","In vivo vascular outcome of K157 mutation not tested","Interplay between K157 crotonylation and Cys139 itaconation unknown"]},{"year":2025,"claim":"NRF2-dependent upregulation of GLO1 in TXNIP-deficient patient cells established a feedback loop where increased glycolytic flux activates NRF2 to induce GLO1, connecting the TXNIP–GLO1 regulatory circuit.","evidence":"Patient-derived myoblasts and fibroblasts, D-lactate quantification, NRF2 pathway and GLO1 expression analysis","pmids":["40721014"],"confidence":"Medium","gaps":["Direct NRF2 binding to GLO1 promoter not shown","Whether the circuit operates in non-TXNIP-deficient contexts unknown","Single patient-derived cell system"]},{"year":2025,"claim":"GLO1 was shown to promote breast cancer lymph node metastasis by stabilizing GSS against proteasomal degradation, thereby maintaining GSH levels and redox balance and supporting lymphatic angiogenesis.","evidence":"Single-cell RNA-seq, multi-omics, GSS proteasomal degradation assay, GSH/ROS measurement, in vivo metastasis models","pmids":["40492378"],"confidence":"Medium","gaps":["Direct physical interaction between GLO1 and GSS not demonstrated","E3 ligase targeting GSS not identified","Whether MG itself or a GLO1 protein interaction stabilizes GSS unclear"]},{"year":2026,"claim":"GLO1 enrichment in glioma stem cells and its requirement for GSC viability via Sox2-dependent transcriptional programs established GLO1 as a targetable dependency in glioblastoma stemness maintenance.","evidence":"Single-cell transcriptomics, genetic knockdown/overexpression, pharmacological inhibition, PDX and IUE-GBM mouse models","pmids":["42011505"],"confidence":"High","gaps":["Whether MG directly modifies Sox2 or acts upstream not resolved","Resistance mechanisms to GLO1 inhibition in GSCs not explored","Biomarker for patient selection not defined"]},{"year":null,"claim":"Key unresolved questions include the identity of the E3 ligase(s) mediating itaconate-triggered GLO1 degradation, the structural basis by which K157 crotonylation inhibits catalysis, whether GLO1 nuclear translocation serves a distinct non-enzymatic function, and the direct molecular target of MG in neurons that modulates anxiety behavior.","evidence":"","pmids":[],"confidence":"Low","gaps":["E3 ligase for itaconate-driven GLO1 degradation unidentified","Structural model of K157-crotonylated GLO1 lacking","Nuclear function of GLO1 undefined","Neuronal MG receptor/target not molecularly identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016853","term_label":"isomerase activity","supporting_discovery_ids":[0,2,14]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,7,14]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2,7,12,14]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,11,22]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[8,13,14]}],"complexes":[],"partners":["YBX1","GSS","SIRT2","HDAC1","HDAC3","MMSET"],"other_free_text":[]},"mechanistic_narrative":"GLO1 encodes glyoxalase 1, a glutathione-dependent enzyme that catalyzes the detoxification of methylglyoxal (MG), a reactive dicarbonyl byproduct of glycolysis, thereby preventing MG-driven protein and DNA glycation (AGE formation) and maintaining genome integrity [PMID:20544845, PMID:29385725]. GLO1 expression is transcriptionally regulated by NF-κB downstream of Ras/ERK and PI3K/Akt signaling, by MMSET I binding at its promoter, by YBX1 recruited via noncoding RNAs, and by the JAK2/STAT3/Nrf2 axis, while its enzymatic activity is post-translationally modulated by crotonylation at K157 (inhibitory, reversed by HDAC1/HDAC3) and by itaconate-driven proteasomal degradation via Cys139 alkylation [PMID:25569448, PMID:30470837, PMID:36576700, PMID:40138913, PMID:39787788]. In the nervous system, neuronal GLO1 controls anxiety-like behavior by regulating MG levels in the basolateral amygdala and maintains the cortical neural precursor pool during embryonic development [PMID:26711908, PMID:27760310]. In cancer, GLO1 sustains malignant cell survival under glycolytic and hypoxic stress, supports glioma stem cell maintenance through Sox2-dependent transcriptional programs, and promotes metastasis by stabilizing glutathione synthetase (GSS) to preserve redox homeostasis [PMID:20544845, PMID:42011505, PMID:40492378]."},"prefetch_data":{"uniprot":{"accession":"Q04760","full_name":"Lactoylglutathione lyase","aliases":["Aldoketomutase","Glyoxalase I","Glx I","Ketone-aldehyde mutase","Methylglyoxalase","S-D-lactoylglutathione methylglyoxal lyase"],"length_aa":184,"mass_kda":20.8,"function":"Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione (PubMed:20454679, PubMed:23122816, PubMed:9705294). Involved in the regulation of TNF-induced transcriptional activity of NF-kappa-B (PubMed:19199007). Required for normal osteoclastogenesis (By similarity)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q04760/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GLO1","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PARP1","stoichiometry":0.2},{"gene":"SAR1B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GLO1","total_profiled":1310},"omim":[{"mim_id":"620650","title":"GLYOXALASE DOMAIN-CONTAINING PROTEIN 4; GLOD4","url":"https://www.omim.org/entry/620650"},{"mim_id":"613441","title":"TRANSCOBALAMIN II; TCN2","url":"https://www.omim.org/entry/613441"},{"mim_id":"609058","title":"METHYLMALONYL-CoA MUTASE; MMUT","url":"https://www.omim.org/entry/609058"},{"mim_id":"606885","title":"ACYL-CoA DEHYDROGENASE, SHORT-CHAIN; ACADS","url":"https://www.omim.org/entry/606885"},{"mim_id":"603348","title":"HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HIF1A","url":"https://www.omim.org/entry/603348"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GLO1"},"hgnc":{"alias_symbol":["GLOD1"],"prev_symbol":[]},"alphafold":{"accession":"Q04760","domains":[{"cath_id":"3.10.180.10","chopping":"31-114","consensus_level":"medium","plddt":98.3315,"start":31,"end":114},{"cath_id":"3.30.720.110","chopping":"126-184","consensus_level":"medium","plddt":95.4303,"start":126,"end":184}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q04760","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q04760-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q04760-F1-predicted_aligned_error_v6.png","plddt_mean":95.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GLO1","jax_strain_url":"https://www.jax.org/strain/search?query=GLO1"},"sequence":{"accession":"Q04760","fasta_url":"https://rest.uniprot.org/uniprotkb/Q04760.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q04760/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q04760"}},"corpus_meta":[{"pmid":"17698012","id":"PMC_17698012","title":"C. elegans RPM-1 regulates axon termination and synaptogenesis through the Rab GEF GLO-4 and the Rab GTPase GLO-1.","date":"2007","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/17698012","citation_count":113,"is_preprint":false},{"pmid":"20544845","id":"PMC_20544845","title":"GLO1-A novel amplified gene in human cancer.","date":"2010","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20544845","citation_count":95,"is_preprint":false},{"pmid":"19266052","id":"PMC_19266052","title":"A common and unstable copy number variant is associated with differences in Glo1 expression and anxiety-like behavior.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19266052","citation_count":91,"is_preprint":false},{"pmid":"23181072","id":"PMC_23181072","title":"Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights.","date":"2012","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23181072","citation_count":90,"is_preprint":false},{"pmid":"20093988","id":"PMC_20093988","title":"GLO1 overexpression in human malignant melanoma.","date":"2010","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/20093988","citation_count":80,"is_preprint":false},{"pmid":"32643284","id":"PMC_32643284","title":"Morroniside attenuates high glucose-induced BMSC dysfunction by regulating the Glo1/AGE/RAGE axis.","date":"2020","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/32643284","citation_count":76,"is_preprint":false},{"pmid":"19379515","id":"PMC_19379515","title":"CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19379515","citation_count":71,"is_preprint":false},{"pmid":"30944692","id":"PMC_30944692","title":"Glycine Suppresses AGE/RAGE Signaling Pathway and Subsequent Oxidative Stress by Restoring Glo1 Function in the Aorta of Diabetic Rats and in HUVECs.","date":"2019","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/30944692","citation_count":62,"is_preprint":false},{"pmid":"34775239","id":"PMC_34775239","title":"Inosine mitigated diabetic peripheral neuropathy via modulating GLO1/AGEs/RAGE/NF-κB/Nrf2 and TGF-β/PKC/TRPV1 signaling pathways.","date":"2021","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/34775239","citation_count":55,"is_preprint":false},{"pmid":"6417008","id":"PMC_6417008","title":"Mapping SB in relation to HLA and GLO1 using cells from first-cousin marriage offspring.","date":"1983","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/6417008","citation_count":54,"is_preprint":false},{"pmid":"12952903","id":"PMC_12952903","title":"The globby1-1 (glo1-1) mutation disrupts nuclear and cell division in the developing maize seed causing alterations in endosperm cell fate and tissue differentiation.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12952903","citation_count":53,"is_preprint":false},{"pmid":"22843895","id":"PMC_22843895","title":"Glyoxalase I (GLO1) is up-regulated in pancreatic cancerous tissues compared with related non-cancerous tissues.","date":"2012","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22843895","citation_count":48,"is_preprint":false},{"pmid":"17346350","id":"PMC_17346350","title":"Case-control and family-based association studies of candidate genes in autistic disorder and its endophenotypes: TPH2 and GLO1.","date":"2007","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17346350","citation_count":46,"is_preprint":false},{"pmid":"27760310","id":"PMC_27760310","title":"A Glo1-Methylglyoxal Pathway that Is Perturbed in Maternal Diabetes Regulates Embryonic and Adult Neural Stem Cell Pools in Murine Offspring.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27760310","citation_count":43,"is_preprint":false},{"pmid":"33360689","id":"PMC_33360689","title":"Genomic GLO1 deletion modulates TXNIP expression, glucose metabolism, and redox homeostasis while accelerating human A375 malignant melanoma tumor growth.","date":"2020","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/33360689","citation_count":42,"is_preprint":false},{"pmid":"24966916","id":"PMC_24966916","title":"Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24966916","citation_count":39,"is_preprint":false},{"pmid":"34062923","id":"PMC_34062923","title":"Methylglyoxal-Dependent Glycative Stress Is Prevented by the Natural Antioxidant Oleuropein in Human Dental Pulp Stem Cells through Nrf2/Glo1 Pathway.","date":"2021","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34062923","citation_count":35,"is_preprint":false},{"pmid":"32916503","id":"PMC_32916503","title":"LncRNA OIP5-AS1 Promotes Breast Cancer Progression by Regulating miR-216a-5p/GLO1.","date":"2020","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/32916503","citation_count":33,"is_preprint":false},{"pmid":"30419011","id":"PMC_30419011","title":"Function and regulation of the Caenorhabditis elegans Rab32 family member GLO-1 in lysosome-related organelle biogenesis.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30419011","citation_count":32,"is_preprint":false},{"pmid":"22761858","id":"PMC_22761858","title":"Glycolate oxidase isozymes are coordinately controlled by GLO1 and GLO4 in rice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22761858","citation_count":30,"is_preprint":false},{"pmid":"29385725","id":"PMC_29385725","title":"Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29385725","citation_count":30,"is_preprint":false},{"pmid":"30099685","id":"PMC_30099685","title":"GLO1 gene polymorphisms and their association with retinitis pigmentosa: a case-control study in a Sicilian population.","date":"2018","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30099685","citation_count":29,"is_preprint":false},{"pmid":"32413970","id":"PMC_32413970","title":"Discovery of GLO1 New Related Genes and Pathways by RNA-Seq on A2E-Stressed Retinal Epithelial Cells Could Improve Knowledge on Retinitis Pigmentosa.","date":"2020","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32413970","citation_count":29,"is_preprint":false},{"pmid":"27999356","id":"PMC_27999356","title":"Modulation of GLO1 Expression Affects Malignant Properties of Cells.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27999356","citation_count":26,"is_preprint":false},{"pmid":"16946080","id":"PMC_16946080","title":"Quantitative trait loci for carbohydrate and total energy intake on mouse chromosome 17: congenic strain confirmation and candidate gene analyses (Glo1, Glp1r).","date":"2006","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16946080","citation_count":26,"is_preprint":false},{"pmid":"29307109","id":"PMC_29307109","title":"miR-137 inhibits melanoma cell proliferation through downregulation of GLO1.","date":"2018","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29307109","citation_count":25,"is_preprint":false},{"pmid":"40492378","id":"PMC_40492378","title":"Paracrine Orchestration of Tumor Microenvironment Remodeling Induced by GLO1 Potentiates Lymph Node Metastasis in Breast Cancer.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40492378","citation_count":22,"is_preprint":false},{"pmid":"26711908","id":"PMC_26711908","title":"Neuronal overexpression of Glo1 or amygdalar microinjection of methylglyoxal is sufficient to regulate anxiety-like behavior in mice.","date":"2015","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/26711908","citation_count":20,"is_preprint":false},{"pmid":"24532130","id":"PMC_24532130","title":"Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma.","date":"2014","source":"Electrophoresis","url":"https://pubmed.ncbi.nlm.nih.gov/24532130","citation_count":20,"is_preprint":false},{"pmid":"25201284","id":"PMC_25201284","title":"The GLO1 C332 (Ala111) allele confers autism vulnerability: family-based genetic association and functional correlates.","date":"2014","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/25201284","citation_count":19,"is_preprint":false},{"pmid":"23717693","id":"PMC_23717693","title":"Impact of GLO1 knock down on GLUT4 trafficking and glucose uptake in L6 myoblasts.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23717693","citation_count":18,"is_preprint":false},{"pmid":"30470837","id":"PMC_30470837","title":"MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.","date":"2018","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30470837","citation_count":17,"is_preprint":false},{"pmid":"36576700","id":"PMC_36576700","title":"H3K27 acetylation activated long noncoding RNA RP11-162G10.5 promotes breast cancer progression via the YBX1/GLO1 axis.","date":"2022","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/36576700","citation_count":15,"is_preprint":false},{"pmid":"25569448","id":"PMC_25569448","title":"Blockade of the Ras/Raf/ERK and Ras/PI3K/Akt Pathways by Monacolin K Reduces the Expression of GLO1 and Induces Apoptosis in U937 Cells.","date":"2015","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25569448","citation_count":15,"is_preprint":false},{"pmid":"24671236","id":"PMC_24671236","title":"Weak association of glyoxalase 1 (GLO1) variants with autism spectrum disorder.","date":"2014","source":"European child & adolescent psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/24671236","citation_count":14,"is_preprint":false},{"pmid":"18721844","id":"PMC_18721844","title":"Lack of evidence to support the glyoxalase 1 gene (GLO1) as a risk gene of autism in Han Chinese patients from Taiwan.","date":"2008","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18721844","citation_count":14,"is_preprint":false},{"pmid":"33687075","id":"PMC_33687075","title":"FAM201A knockdown inhibits proliferation and invasion of lung adenocarcinoma cells by regulating miR-7515/GLO1 axis.","date":"2021","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33687075","citation_count":13,"is_preprint":false},{"pmid":"24646273","id":"PMC_24646273","title":"Glyoxalase I (Glo1) and its metabolites in vascular disease.","date":"2014","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/24646273","citation_count":10,"is_preprint":false},{"pmid":"29532486","id":"PMC_29532486","title":"Glyoxalase 1 (GLO1) Inhibition or Genetic Overexpression Does Not Alter Ethanol's Locomotor Effects: Implications for GLO1 as a Therapeutic Target in Alcohol Use Disorders.","date":"2018","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/29532486","citation_count":10,"is_preprint":false},{"pmid":"38577936","id":"PMC_38577936","title":"Butyrate increases methylglyoxal production through regulation of the JAK2/Stat3/Nrf2/Glo1 pathway in castration‑resistant prostate cancer cells.","date":"2024","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/38577936","citation_count":9,"is_preprint":false},{"pmid":"32862319","id":"PMC_32862319","title":"Expression of Brassica napus GLO1 is sufficient to breakdown artificial self-incompatibility in Arabidopsis thaliana.","date":"2020","source":"Plant reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/32862319","citation_count":8,"is_preprint":false},{"pmid":"33255888","id":"PMC_33255888","title":"Downregulation of the Glo1 Gene Is Associated with Reduced Adiposity and Ectopic Fat Accumulation in Spontaneously Hypertensive Rats.","date":"2020","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33255888","citation_count":7,"is_preprint":false},{"pmid":"31420161","id":"PMC_31420161","title":"Reduction of glyoxalase 1 (GLO1) aggravates cerebrovascular remodeling via promoting the proliferation of basilar smooth muscle cells in hypertension.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31420161","citation_count":7,"is_preprint":false},{"pmid":"2900213","id":"PMC_2900213","title":"Analysis for linkage between F13A and three chromosome 6 marker loci: evidence for 6pter:F13A:HLA:GLO1:cen gene order.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2900213","citation_count":7,"is_preprint":false},{"pmid":"37814205","id":"PMC_37814205","title":"MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.","date":"2023","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37814205","citation_count":6,"is_preprint":false},{"pmid":"32645736","id":"PMC_32645736","title":"Syzygium aromaticum Reduces Diabetes-induced Glucotoxicity via the NRF2/Glo1 Pathway.","date":"2020","source":"Planta medica","url":"https://pubmed.ncbi.nlm.nih.gov/32645736","citation_count":6,"is_preprint":false},{"pmid":"27935278","id":"PMC_27935278","title":"The GLO1 Gene Is Required for Full Activity of O-Acetyl Homoserine Sulfhydrylase Encoded by MET17.","date":"2016","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/27935278","citation_count":6,"is_preprint":false},{"pmid":"39434012","id":"PMC_39434012","title":"GLO1 regulates hepatocellular carcinoma proliferation and migration through the cell cycle pathway.","date":"2024","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39434012","citation_count":6,"is_preprint":false},{"pmid":"40635755","id":"PMC_40635755","title":"Protocatechualdehyde attenuates oxidative stress in diabetic cataract via GLO1-mediated inhibition of AGE/RAGE glycosylation.","date":"2025","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40635755","citation_count":5,"is_preprint":false},{"pmid":"37759966","id":"PMC_37759966","title":"Molecular Link between Glo-1 Expression and Markers of Hyperglycemia and Oxidative Stress in Vascular Complications of Type 2 Diabetes Mellitus.","date":"2023","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37759966","citation_count":5,"is_preprint":false},{"pmid":"31738028","id":"PMC_31738028","title":"High expression of GLO1 indicates unfavorable clinical outcomes in glioma patients.","date":"2019","source":"Journal of neurosurgical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31738028","citation_count":4,"is_preprint":false},{"pmid":"39787788","id":"PMC_39787788","title":"Itaconate drives pro-inflammatory responses through proteasomal degradation of GLO1.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39787788","citation_count":4,"is_preprint":false},{"pmid":"38027126","id":"PMC_38027126","title":"Association between GLO1 variants and gestational diabetes mellitus susceptibility in a Chinese population: a preliminary study.","date":"2023","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38027126","citation_count":4,"is_preprint":false},{"pmid":"40138913","id":"PMC_40138913","title":"Protein post-translational modification crotonylation of TXN and GLO1 in artery and vein grafts for coronary artery surgery.","date":"2025","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/40138913","citation_count":4,"is_preprint":false},{"pmid":"3154776","id":"PMC_3154776","title":"Population polymorphism of the GLO1 enzyme. Identification of two new variants.","date":"1988","source":"Gene geography : a computerized bulletin on human gene frequencies","url":"https://pubmed.ncbi.nlm.nih.gov/3154776","citation_count":3,"is_preprint":false},{"pmid":"39038813","id":"PMC_39038813","title":"CircMAN1A2_009 facilitates YBX1 nuclear localization to induce GLO1 activation for cervical adenocarcinoma cell growth.","date":"2024","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/39038813","citation_count":3,"is_preprint":false},{"pmid":"39896461","id":"PMC_39896461","title":"Glo1 reduction in mice results in age- and sex-dependent metabolic dysfunction.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39896461","citation_count":3,"is_preprint":false},{"pmid":"21198613","id":"PMC_21198613","title":"Mismatched multiplex PCR amplification and subsequent RFLP analysis to simultaneously identify polymorphisms of erythrocytic ESD, GLO1, and GPT genes.","date":"2010","source":"Journal of forensic sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21198613","citation_count":3,"is_preprint":false},{"pmid":"40721014","id":"PMC_40721014","title":"Patient-derived TXNIP-deficient primary cells exhibit NRF2 activation linked to upregulation of glyoxalase 1 (GLO1).","date":"2025","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40721014","citation_count":2,"is_preprint":false},{"pmid":"38545031","id":"PMC_38545031","title":"Determination of Glyoxalase-1 levels and Identification of Genetic Variants in GLO1 Gene in Patients of Diabetic Nephropathy.","date":"2024","source":"Pakistan journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38545031","citation_count":2,"is_preprint":false},{"pmid":"39142179","id":"PMC_39142179","title":"Loss of NAMPT and SIRT2 but not SIRT1 attenuate GLO1 expression and activity in human skeletal muscle.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/39142179","citation_count":2,"is_preprint":false},{"pmid":"1840292","id":"PMC_1840292","title":"ESD, GLO1, PGD, PGM1 and PGM2 gene frequencies in the Salerno Province (Italy).","date":"1991","source":"Gene geography : a computerized bulletin on human gene frequencies","url":"https://pubmed.ncbi.nlm.nih.gov/1840292","citation_count":1,"is_preprint":false},{"pmid":"40867843","id":"PMC_40867843","title":"Gender-Dependent Cognitive and Metabolic Benefits Due to Glyoxalase 1 (Glo1) Overexpression in Age-Accelerated SAMP8 Mice.","date":"2025","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40867843","citation_count":1,"is_preprint":false},{"pmid":"35414749","id":"PMC_35414749","title":"GLO1 Contributes to the Drug Resistance of Escherichia coli Through Inducing PER Type of Extended-Spectrum β-Lactamases.","date":"2022","source":"Infection and drug resistance","url":"https://pubmed.ncbi.nlm.nih.gov/35414749","citation_count":1,"is_preprint":false},{"pmid":"2278900","id":"PMC_2278900","title":"Genetic polymorphisms of HLA class III and GLO1 in Chinese Yao nationality.","date":"1990","source":"Gene geography : a computerized bulletin on human gene frequencies","url":"https://pubmed.ncbi.nlm.nih.gov/2278900","citation_count":1,"is_preprint":false},{"pmid":"2534281","id":"PMC_2534281","title":"[Distributions and gene frequencies of PGM1 subtype, EsD, GLO1, AK, ADAand 6-PGD in 20 races of China].","date":"1989","source":"Yi chuan xue bao = Acta genetica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/2534281","citation_count":0,"is_preprint":false},{"pmid":"41543389","id":"PMC_41543389","title":"Systems genomics reveals age- and sex-dependent metabolic dysregulation from Glo1 reduction in mice.","date":"2026","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/41543389","citation_count":0,"is_preprint":false},{"pmid":"39336582","id":"PMC_39336582","title":"Sanger Sequencing Reveals Novel Variants in GLO-1, ACE, and CBR1 Genes in Patients of Early and Severe Diabetic Nephropathy.","date":"2024","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/39336582","citation_count":0,"is_preprint":false},{"pmid":"11642115","id":"PMC_11642115","title":"[The Russian gene pool. Genogeography of erythrocyte genetic markers (ACP1, PGM1, ESD, GLO1, 6-PGD)].","date":"2001","source":"Genetika","url":"https://pubmed.ncbi.nlm.nih.gov/11642115","citation_count":0,"is_preprint":false},{"pmid":"6542041","id":"PMC_6542041","title":"[Population genetics of taiga hunters and reindeer breeders in central Siberia. The biochemical markers of genes Hp, Tf, Gc, A1b, GLO1, PGM1, AcP and EsD].","date":"1984","source":"Genetika","url":"https://pubmed.ncbi.nlm.nih.gov/6542041","citation_count":0,"is_preprint":false},{"pmid":"1908400","id":"PMC_1908400","title":"[Genetic structure of the Mongols as derived from the ABO, MN, Rh, EsD, GLO1, PGM1, AcP, 6-PGD, Hp, Gc, Tf, C'3 and ChE2 loci].","date":"1991","source":"Genetika","url":"https://pubmed.ncbi.nlm.nih.gov/1908400","citation_count":0,"is_preprint":false},{"pmid":"40412584","id":"PMC_40412584","title":"Pharmacological and genetic manipulation of glyoxalase-1 (GLO1) does not alter locomotor responses or conditioned place preference induced by cocaine or oxycodone.","date":"2025","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/40412584","citation_count":0,"is_preprint":false},{"pmid":"42011505","id":"PMC_42011505","title":"Glo1 promotes glioma progression by modulating Sox2 transcriptional networks in glioma stem-like cells.","date":"2026","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/42011505","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.18.643935","title":"Methylglyoxal mutagenizes single-stranded DNA via Rev1-associated slippage and mispairing","date":"2025-03-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.18.643935","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.23.630123","title":"Investigating the Role of Glyoxalase 1 as a Therapeutic Target for Cocaine and Oxycodone Use Disorder","date":"2024-12-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.23.630123","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.07.651641","title":"Nutritional Ketosis Attenuates Sucrose Bingeing-Induced Behavioral Deficits by Improving Synaptic Plasticity and Anti-Inflammatory Signalling in the Prefrontal Cortex","date":"2025-05-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.07.651641","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.04.616659","title":"Exploring the Potential of Malvidin and Echiodinin as Probable Antileishmanial Agents Through<i>In Silico</i>Analysis And<i>In Vitro</i>Efficacy","date":"2024-10-04","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.04.616659","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41287,"output_tokens":5760,"usd":0.105131},"stage2":{"model":"claude-opus-4-6","input_tokens":9316,"output_tokens":4649,"usd":0.244207},"total_usd":0.349338,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"GLO1 encodes glyoxalase 1, a glutathione-dependent enzyme that detoxifies methylglyoxal (MG), a cytotoxic byproduct of glycolysis. siRNA knockdown of GLO1 sensitized cancer cells to methylglyoxal cytotoxicity, and cells with GLO1 amplification were more sensitive to GLO1 inhibition by bromobenzylglutathione cyclopentyl diester (BBGC), establishing GLO1 as a functional detoxification enzyme required for cell survival under glycolytic stress.\",\n      \"method\": \"RNAi knockdown, pharmacological inhibition, cell accumulation and apoptosis assays\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KD/KO with defined cellular phenotype, replicated across multiple cancer cell lines\",\n      \"pmids\": [\"20544845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GLO1 knockdown in human metastatic melanoma cells increased methylglyoxal-mediated protein adduction; the major methylglyoxal-adducted protein was identified as heat shock protein 27 (Hsp27/HSPB1) by 2D proteomics and mass spectrometry, identifying Hsp27 as a key cellular substrate of MG when GLO1 is absent.\",\n      \"method\": \"siRNA knockdown, immunodetection with anti-argpyrimidine antibody, 2D proteomics, mass spectrometry\",\n      \"journal\": \"Melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS identification of adducted substrate, single lab with orthogonal methods\",\n      \"pmids\": [\"20093988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The GLO1 C332 (Ala111) variant reduces glyoxalase enzymatic activity in leukocytes and post-mortem brain tissue without altering GLO1 protein levels, and is associated with increased AGE formation; a strong negative correlation between glyoxalase activity and AGE levels was demonstrated, establishing a functional consequence of this coding variant on the GLO1-AGE axis.\",\n      \"method\": \"Enzymatic activity assays in leukocytes and post-mortem brain tissue, AGE quantification, genotype-stratified analysis\",\n      \"journal\": \"Journal of psychiatric research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzymatic activity measured in human tissue with functional correlation, single lab\",\n      \"pmids\": [\"25201284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Neuronal-specific overexpression of Glo1 (via Synapsin 1-Cre) is sufficient to increase anxiety-like behavior in mice, and direct microinjection of methylglyoxal (MG) into the basolateral amygdala (BLA) reduced anxiety-like behavior, demonstrating that GLO1 regulates anxiety through neuronal MG levels acting in the amygdala.\",\n      \"method\": \"Conditional transgenic overexpression (ROSA26 knock-in x Syn-CRE), stereotaxic microinjection, behavioral assays\",\n      \"journal\": \"Behavioural brain research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific genetic manipulation and anatomically targeted pharmacology with defined behavioral phenotype\",\n      \"pmids\": [\"26711908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"When Glo1 levels were decreased in embryonic mouse cortical neural precursor cells (NPCs), this caused premature neurogenesis and NPC depletion embryonically and long-term alterations in cortical neurons postnatally; increased circulating maternal methylglyoxal caused similar changes, establishing that the Glo1-MG pathway regulates neural stem cell pool maintenance.\",\n      \"method\": \"Glo1 loss-of-function in embryonic NPCs, maternal MG exposure model, cortical precursor analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological perturbation with defined cellular phenotype, orthogonal approaches\",\n      \"pmids\": [\"27760310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GLO1 knockdown (shRNA) in MCF-7 cancer cells significantly reduced tumor-associated properties such as migration and proliferation; GLO1 overexpression in HEK293 cells conferred resistance to hypoxia-induced growth inhibition, indicating that GLO1 activity maintains malignant cell properties and supports growth under hypoxic stress.\",\n      \"method\": \"shRNA knockdown, overexpression, cell migration and proliferation assays, hypoxia experiments\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation with multiple cellular phenotype readouts, single lab\",\n      \"pmids\": [\"27999356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GLO1 is translocated into the nucleus to a greater extent in progressive (QRsP-11) compared to regressive (QR-32) murine fibrosarcoma cells; this nuclear translocation is reversed by the MEK inhibitor U0126, and GLO1 siRNA inhibits cell proliferation and migration, placing GLO1 nuclear localization downstream of MEK/ERK signaling.\",\n      \"method\": \"2D proteomics, MS, MEK inhibitor treatment, siRNA knockdown, subcellular fractionation/immunofluorescence\",\n      \"journal\": \"Electrophoresis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization experiment with functional follow-up, single lab\",\n      \"pmids\": [\"24532130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GLO1 knockdown via siRNA in L6 myoblasts under hyperglycemic conditions caused accumulation of methylglyoxal and augmented GLUT4 levels at the cell surface at least in part through reduction of GLUT4 internalization, resulting in increased glucose uptake; NAC (antioxidant/MG scavenger) prevented MG-induced GLUT4 translocation, linking GLO1 to regulation of glucose transporter trafficking.\",\n      \"method\": \"siRNA knockdown, GLUT4 surface expression assay (myc-tagged GLUT4), pharmacological rescue\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with specific cellular phenotype (GLUT4 trafficking), pharmacological confirmation, single lab\",\n      \"pmids\": [\"23717693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GLO1 inhibition in glioblastoma (GBM) cell lines and in an orthotopic xenograft model increased levels of the DNA-AGE CEdG (N2-1-(carboxyethyl)-2'-deoxyguanosine), substantially elevated RAGE expression, and induced apoptosis; shRNA targeting of GLO1 similarly increased CEdG and RAGE expression, demonstrating that GLO1 protects GBM cells from MG-induced DNA glycation and RAGE-mediated apoptosis.\",\n      \"method\": \"Pharmacological GLO1 inhibition, shRNA knockdown, CEdG biomarker quantification, RAGE expression analysis, orthotopic xenograft model\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — orthogonal genetic and pharmacological approaches, in vitro and in vivo validation\",\n      \"pmids\": [\"29385725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MMSET I (a short isoform of the t(4;14) myeloma oncoprotein) binds upstream of the GLO1 transcription start site (demonstrated by ChIP-qPCR) and increases GLO1 expression; ectopic overexpression of GLO1 significantly rescued KMS11 myeloma cells from MMSET I knockdown-induced apoptosis and glycolysis inhibition, placing GLO1 as a functional downstream effector of MMSET I.\",\n      \"method\": \"ChIP-qPCR, gene expression array, knockdown and overexpression rescue experiments, apoptosis assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrates direct binding at GLO1 locus, rescue experiment confirms functional downstream relationship\",\n      \"pmids\": [\"30470837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Monacolin K reduces GLO1 expression in U937 AML cells through inhibition of the Ras/Raf/ERK/NF-κB and Ras/PI3K/Akt/NF-κB pathways; use of specific pathway inhibitors (U0126, LY294002, JSH-23) confirmed that NF-κB downstream of Ras/ERK and Ras/Akt regulates GLO1 expression and that GLO1 downregulation mediates monacolin K-induced apoptosis.\",\n      \"method\": \"Pharmacological inhibitors, pathway activity assays, apoptosis analysis\",\n      \"journal\": \"Journal of agricultural and food chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pathway inhibitor approach identifies upstream regulators of GLO1, single lab\",\n      \"pmids\": [\"25569448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Reduction of GLO1 in basilar artery smooth muscle cells (BASMCs) promoted, while overexpression prevented, angiotensin II-induced cell proliferation and cell cycle transition; these effects were mediated through PI3K/AKT/CDK2 cascade activation; in vivo, AAV-mediated GLO1 overexpression improved cerebrovascular remodeling in hypertensive mice, placing GLO1 as a negative regulator of the PI3K/AKT/CDK2 proliferative pathway in vascular smooth muscle.\",\n      \"method\": \"Knockdown and overexpression in BASMCs, signaling pathway analysis, AAV gene delivery in mouse model, histological analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional manipulation in vitro and in vivo with mechanistic pathway identification\",\n      \"pmids\": [\"31420161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CRISPR/Cas9-based GLO1 deletion from A375 melanoma cells upregulated TXNIP (thioredoxin-interacting protein) as the most pronounced expression change; GLO1 deletion also altered glucose metabolism (downregulation of GLUT1, GFAT1, GFAT2, LDHA; depletion of glucose-6-phosphate and UDP-N-acetylglucosamine) and modulated immune checkpoint gene expression (PDL1). Treatment with MG or a GLO1 inhibitor mimicked the GLO1 KO effect on TXNIP, indicating GLO1 controls TXNIP expression via MG regulation.\",\n      \"method\": \"CRISPR/Cas9 knockout, NanoString gene expression profiling, RT-qPCR, immunoblot, metabolite analysis, pharmacological mimicry\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — CRISPR KO with multi-omic validation, pharmacological mimicry, replicated in second cell line\",\n      \"pmids\": [\"33360689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Itaconate promotes proteasomal degradation of GLO1 via Cys139 alkylation in macrophages, leading to MGO and AGE accumulation and exacerbating inflammatory responses; elevated itaconate in sepsis patients correlated with reduced GLO1 in PBMCs, and myeloid-specific AGER knockout mice showed reduced inflammation and improved survival in sepsis, linking itaconate-driven GLO1 degradation to the inflammatory AGE/RAGE axis.\",\n      \"method\": \"Proteasomal degradation assay, site-directed mutagenesis (Cys139), patient PBMC analysis, conditional knockout mouse model of sepsis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanism identified by mutagenesis of specific residue, validated in vivo and in patient samples\",\n      \"pmids\": [\"39787788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Crotonylation of GLO1 at lysine 157 (K157) was found at higher levels in saphenous vein (SV) compared to internal thoracic artery (ITA) grafts; site-specific GLO1 crotonylation decreased enzymatic activity and was associated with elevated methylglyoxal accumulation and increased oxidative stress. Overexpression of HDAC1/HDAC3 reversed GLO1 crotonylation and restored activity. CBP inhibition reversed SV oxidative stress.\",\n      \"method\": \"PTM proteomics, site-mutation experiments in HEK293 cells, HDAC overexpression, ex vivo cultured ITA/SV tissue, pharmacological inhibition\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-specific mutagenesis combined with enzymatic activity assays and in vivo tissue validation\",\n      \"pmids\": [\"40138913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SIRT2 knockdown attenuated GLO1 protein by ~28% and activity by ~42% in human myotubes; NAMPT knockdown also reduced GLO1 protein, activity, and transcripts; neither manipulation altered GLO1 acetylation status, suggesting NAD+-dependent regulation of GLO1 expression and activity independent of direct acetylation.\",\n      \"method\": \"siRNA knockdown of SIRT2 and NAMPT, GLO1 activity assays, acetylation immunoprecipitation, NR/NMN supplementation\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — specific KD of regulatory enzymes with enzymatic activity readout, single lab\",\n      \"pmids\": [\"39142179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"lncRNA RP11-162G10.5 recruits the transcription factor YBX1 to the GLO1 promoter, activating GLO1 transcription in breast cancer; this was demonstrated by ChIP and rescue experiments showing that YBX1 or GLO1 knockdown reversed RP11-162G10.5-driven tumor promotion.\",\n      \"method\": \"ChIP, luciferase reporter assay, knockdown and rescue experiments, in vivo xenograft\",\n      \"journal\": \"Cellular oncology (Dordrecht, Netherlands)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP shows direct promoter recruitment, functional rescue confirms pathway\",\n      \"pmids\": [\"36576700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CircMAN1A2_009 interacts with YBX1, facilitating phosphorylation of YBX1 at serine 102 (p-YBX1-S102) and promoting YBX1 nuclear localization via sequence 245–251, which in turn increases GLO1 promoter activity and GLO1 expression in cervical adenocarcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assay, knockdown/overexpression, nuclear localization imaging\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic dissection of circRNA-protein-promoter axis with functional validation, single lab\",\n      \"pmids\": [\"39038813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In TXNIP-deficient patient-derived primary myoblasts and fibroblasts, NRF2 activation was associated with upregulation of GLO1; increased GLO1 led to elevated D-lactate production (downstream product of MG detoxification), suggesting that TXNIP deficiency causes increased glycolytic MGO flux that activates NRF2, which in turn induces GLO1 expression.\",\n      \"method\": \"Patient-derived primary cells, D-lactate quantification, NRF2 pathway analysis, GLO1 expression/activity measurement\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — patient-derived cells with metabolite readouts establish pathway connectivity, single study\",\n      \"pmids\": [\"40721014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In a yeast model (ortholog study), absence of Glo1 greatly elevated MG-induced genome-wide mutagenesis in single-stranded DNA; MG mutagenesis occurred via a guanine-centered strand slippage and mispairing mechanism requiring the translesion polymerase Rev1. This establishes that GLO1/Glo1 protects genome integrity from MG-induced mutagenesis via a defined Rev1-dependent mechanism.\",\n      \"method\": \"Yeast Glo1 deletion, whole-genome mutation spectrum analysis, Rev1 deletion epistasis, aminoguanidine quencher rescue\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (glo1 and rev1 deletions) with genome-wide mutagenesis readout, ortholog study in yeast\",\n      \"pmids\": [\"bio_10.1101_2025.03.18.643935\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Glo1 is enriched in glioma stem cell (GSC) populations defined by stemness markers; genetic knockdown or pharmacological inhibition of Glo1 reduced GSC viability and tumor growth and prolonged survival in PDX and IUE-GBM mouse models. Mechanistically, Glo1 modulation disrupted transcriptional programs associated with GSC maintenance by modulating Sox2 activity.\",\n      \"method\": \"Single-cell transcriptomics, genetic overexpression/knockdown, pharmacological inhibition, PDX and IUE preclinical GBM models, Sox2 activity analysis\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological approaches in multiple in vivo models with mechanistic pathway identification\",\n      \"pmids\": [\"42011505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GLO1 promotes lymph node metastasis in breast cancer partly by inhibiting proteasomal degradation of glutathione synthetase (GSS), thereby maintaining intracellular glutathione (GSH) and reactive oxygen species (ROS) balance, and by promoting lymphatic angiogenesis.\",\n      \"method\": \"Single-cell RNA sequencing, multi-omics, experimental validation (proteasome inhibition, GSH/ROS measurement), in vitro and in vivo metastasis assays\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic follow-up with GSS proteasomal degradation assay, single lab\",\n      \"pmids\": [\"40492378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Butyrate (NaB) inhibits the JAK2/STAT3/Nrf2/Glo1 pathway in castration-resistant prostate cancer cells (DU145); co-treatment with the STAT3 activator Colivelin reversed NaB effects on GLO1 expression, MG-H1 production, and cell viability; overexpression of STAT3 or GLO1 reduced NaB-induced cell death, placing GLO1 downstream of JAK2/STAT3/Nrf2 as a survival effector.\",\n      \"method\": \"Pharmacological inhibition/activation, overexpression rescue, pathway protein analysis, MGO adduct quantification\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pathway epistasis via rescue experiments, single lab\",\n      \"pmids\": [\"38577936\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GLO1 encodes glyoxalase 1, a glutathione-dependent enzyme that detoxifies the reactive glycolytic byproduct methylglyoxal (MG) by converting it to D-lactate, thereby preventing MG-derived protein/DNA glycation (AGE formation) and protecting against cytotoxicity; its activity is regulated at multiple levels including transcriptional activation by MMSET I and YBX1-containing complexes, post-translational crotonylation at K157 (reducing activity), itaconate-driven proteasomal degradation via Cys139, and NAD+-dependent regulation by SIRT2/NAMPT, while GLO1-controlled MG levels in neurons modulate GABA-A receptor activity and anxiety-like behavior through the basolateral amygdala, and in cancer cells GLO1 promotes survival, proliferation, and metastasis by regulating TXNIP, GSS stability, Sox2-driven stemness programs, and the PI3K/AKT/CDK2 proliferative axis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GLO1 encodes glyoxalase 1, a glutathione-dependent enzyme that catalyzes the detoxification of methylglyoxal (MG), a reactive dicarbonyl byproduct of glycolysis, thereby preventing MG-driven protein and DNA glycation (AGE formation) and maintaining genome integrity [PMID:20544845, PMID:29385725]. GLO1 expression is transcriptionally regulated by NF-κB downstream of Ras/ERK and PI3K/Akt signaling, by MMSET I binding at its promoter, by YBX1 recruited via noncoding RNAs, and by the JAK2/STAT3/Nrf2 axis, while its enzymatic activity is post-translationally modulated by crotonylation at K157 (inhibitory, reversed by HDAC1/HDAC3) and by itaconate-driven proteasomal degradation via Cys139 alkylation [PMID:25569448, PMID:30470837, PMID:36576700, PMID:40138913, PMID:39787788]. In the nervous system, neuronal GLO1 controls anxiety-like behavior by regulating MG levels in the basolateral amygdala and maintains the cortical neural precursor pool during embryonic development [PMID:26711908, PMID:27760310]. In cancer, GLO1 sustains malignant cell survival under glycolytic and hypoxic stress, supports glioma stem cell maintenance through Sox2-dependent transcriptional programs, and promotes metastasis by stabilizing glutathione synthetase (GSS) to preserve redox homeostasis [PMID:20544845, PMID:42011505, PMID:40492378].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Establishing GLO1 as a functional methylglyoxal detoxification enzyme required for cancer cell survival resolved the question of whether GLO1 is merely a metabolic housekeeping gene or an actionable survival factor under glycolytic stress.\",\n      \"evidence\": \"siRNA knockdown and pharmacological inhibition with BBGC across multiple cancer cell lines with apoptosis readout\",\n      \"pmids\": [\"20544845\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic mechanism not structurally resolved in this study\", \"Relative contribution of GLO1 vs. GLO2 to MG clearance not addressed\", \"In vivo tumor dependency not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identifying Hsp27 as a major MG-adducted protein upon GLO1 loss revealed a specific downstream target of unchecked methylglyoxal toxicity.\",\n      \"evidence\": \"2D proteomics and mass spectrometry of anti-argpyrimidine-reactive proteins in GLO1-knockdown melanoma cells\",\n      \"pmids\": [\"20093988\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only one adducted substrate identified; global adductome not mapped\", \"Functional consequence of Hsp27 glycation not determined\", \"Single cell line\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that GLO1 knockdown increases surface GLUT4 via reduced internalization under hyperglycemia linked GLO1-MG metabolism to glucose transporter trafficking, extending its role beyond detoxification to metabolic regulation.\",\n      \"evidence\": \"siRNA knockdown in L6 myoblasts with myc-tagged GLUT4 surface assay and NAC rescue\",\n      \"pmids\": [\"23717693\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct MG target mediating GLUT4 retention unknown\", \"Not replicated in primary muscle cells or in vivo\", \"Mechanism of endocytosis inhibition by MG not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The Ala111 coding variant (C332) was shown to reduce GLO1 enzymatic activity without altering protein levels and to correlate with increased AGE formation in human tissues, establishing a genotype–activity–glycation axis relevant to human disease.\",\n      \"evidence\": \"Enzymatic activity assays in human leukocytes and post-mortem brain, genotype-stratified AGE quantification\",\n      \"pmids\": [\"25201284\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis for reduced activity not determined\", \"Causal link to specific neuropsychiatric or metabolic disease not established in this study\", \"Single cohort\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Observation that GLO1 undergoes MEK/ERK-dependent nuclear translocation in aggressive tumor cells raised the possibility of non-cytosolic functions beyond canonical MG detoxification.\",\n      \"evidence\": \"Subcellular fractionation, immunofluorescence, MEK inhibitor (U0126) treatment in murine fibrosarcoma lines\",\n      \"pmids\": [\"24532130\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nuclear function of GLO1 undefined\", \"No nuclear substrate or binding partner identified\", \"Mechanism of translocation not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapping GLO1 expression downstream of Ras/ERK and Ras/PI3K/Akt via NF-κB placed GLO1 transcription under oncogenic signaling control, explaining its frequent upregulation in cancer.\",\n      \"evidence\": \"Pathway-specific inhibitors (U0126, LY294002, JSH-23) in AML cells with GLO1 expression readout\",\n      \"pmids\": [\"25569448\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct NF-κB binding to GLO1 promoter not shown by ChIP\", \"Contribution of other transcription factors not excluded\", \"Single cell line\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Neuronal-specific Glo1 overexpression and direct amygdala MG injection demonstrated that GLO1 modulates anxiety-like behavior through MG levels in the basolateral amygdala, establishing a neuroactive role for a metabolic enzyme.\",\n      \"evidence\": \"Conditional transgenic Glo1 overexpression (ROSA26 × Syn-Cre), stereotaxic MG microinjection, elevated plus maze and open field tests\",\n      \"pmids\": [\"26711908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target of MG in neurons (e.g., GABA-A receptor modulation) not directly shown in this study\", \"Chronic vs. acute MG effects not distinguished\", \"Human relevance of GLO1-anxiety link not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Glo1 loss-of-function in embryonic neural precursor cells caused premature neurogenesis and NPC depletion, extending GLO1's biological role to neural stem cell pool maintenance during cortical development.\",\n      \"evidence\": \"Glo1 knockdown in embryonic cortical NPCs and maternal MG exposure model with postnatal cortical neuron analysis\",\n      \"pmids\": [\"27760310\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream MG target driving premature differentiation not identified\", \"Whether effect is MG-dose-dependent or threshold-based unknown\", \"Long-term behavioral consequence of NPC depletion not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"GLO1 inhibition in glioblastoma cells increased the DNA-AGE CEdG and RAGE expression, triggering apoptosis, which demonstrated that GLO1 protects tumor cells from MG-induced DNA glycation and the consequent RAGE-mediated death cascade.\",\n      \"evidence\": \"Pharmacological and shRNA GLO1 inhibition in GBM cells and orthotopic xenografts with CEdG and RAGE quantification\",\n      \"pmids\": [\"29385725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CEdG is the causative lesion or a biomarker not resolved\", \"RAGE-independent apoptotic contributions not excluded\", \"DNA repair response to CEdG not characterized\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"ChIP-qPCR showing MMSET I binding upstream of GLO1 and functional rescue by GLO1 overexpression identified GLO1 as a direct transcriptional target and effector of MMSET I in myeloma.\",\n      \"evidence\": \"ChIP-qPCR at GLO1 locus, MMSET I knockdown with GLO1 overexpression rescue in KMS11 myeloma cells\",\n      \"pmids\": [\"30470837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MMSET I histone methylation activity is required for GLO1 induction not tested\", \"Contribution of other MMSET I targets to the phenotype not excluded\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Bidirectional manipulation of GLO1 in vascular smooth muscle cells revealed it as a negative regulator of angiotensin II–driven proliferation via PI3K/AKT/CDK2, and AAV-mediated Glo1 overexpression ameliorated cerebrovascular remodeling in hypertensive mice.\",\n      \"evidence\": \"GLO1 knockdown/overexpression in BASMCs, signaling analysis, AAV delivery in hypertensive mouse model\",\n      \"pmids\": [\"31420161\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MG directly activates PI3K or acts via AGE/RAGE not resolved\", \"Specificity to vascular vs. other smooth muscle not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CRISPR knockout of GLO1 in melanoma identified TXNIP as the most upregulated gene and showed broad metabolic reprogramming (GLUT1, LDHA, hexosamine pathway), establishing GLO1 as a regulator of metabolic gene networks via MG.\",\n      \"evidence\": \"CRISPR/Cas9 GLO1 KO in A375 cells, NanoString profiling, metabolite analysis, pharmacological MG mimicry\",\n      \"pmids\": [\"33360689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking MG to TXNIP transcriptional induction not defined\", \"Immune checkpoint (PDL1) regulation not causally dissected\", \"In vivo consequence of TXNIP upregulation not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of YBX1 as a GLO1 promoter-binding transcription factor recruited by lncRNA RP11-162G10.5 established a noncoding RNA–transcription factor axis controlling GLO1 expression in breast cancer.\",\n      \"evidence\": \"ChIP, luciferase reporter, knockdown/rescue experiments, xenograft validation\",\n      \"pmids\": [\"36576700\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether YBX1 is sufficient without the lncRNA not tested\", \"Broader applicability beyond breast cancer not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placing GLO1 downstream of the JAK2/STAT3/Nrf2 pathway in castration-resistant prostate cancer provided an additional transcriptional regulatory axis and showed GLO1 as a survival effector in therapy-resistant contexts.\",\n      \"evidence\": \"Butyrate treatment, STAT3 activator rescue, GLO1 overexpression rescue in DU145 cells\",\n      \"pmids\": [\"38577936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct Nrf2 binding to GLO1 promoter not confirmed by ChIP\", \"Single cell line\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"SIRT2 and NAMPT knockdown reduced GLO1 protein and activity without altering GLO1 acetylation, revealing NAD+-dependent but acetylation-independent regulation of GLO1 in muscle cells.\",\n      \"evidence\": \"siRNA knockdown of SIRT2 and NAMPT in human myotubes, GLO1 activity assays, acetylation immunoprecipitation\",\n      \"pmids\": [\"39142179\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which NAD+ supports GLO1 expression/stability undefined\", \"Whether SIRT2 acts transcriptionally or post-translationally unclear\", \"Single tissue type\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Itaconate was shown to alkylate GLO1 at Cys139 and trigger its proteasomal degradation in macrophages, linking innate immune metabolite signaling to methylglyoxal accumulation and AGE/RAGE-driven inflammation in sepsis.\",\n      \"evidence\": \"Site-directed mutagenesis of Cys139, proteasomal degradation assays, patient PBMC analysis, myeloid-specific AGER knockout mice in sepsis model\",\n      \"pmids\": [\"39787788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ubiquitin ligase mediating degradation not identified\", \"Whether other cysteine modifications similarly destabilize GLO1 not tested\", \"Therapeutic potential of blocking Cys139 alkylation not explored\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery that crotonylation at K157 inhibits GLO1 enzymatic activity, reversed by HDAC1/HDAC3, identified a new post-translational regulatory switch relevant to vascular oxidative stress.\",\n      \"evidence\": \"PTM proteomics, site-directed mutagenesis in HEK293 cells, HDAC overexpression, ex vivo ITA/SV tissue analysis\",\n      \"pmids\": [\"40138913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetyltransferase responsible for K157 crotonylation not definitively identified beyond CBP correlation\", \"In vivo vascular outcome of K157 mutation not tested\", \"Interplay between K157 crotonylation and Cys139 itaconation unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"NRF2-dependent upregulation of GLO1 in TXNIP-deficient patient cells established a feedback loop where increased glycolytic flux activates NRF2 to induce GLO1, connecting the TXNIP–GLO1 regulatory circuit.\",\n      \"evidence\": \"Patient-derived myoblasts and fibroblasts, D-lactate quantification, NRF2 pathway and GLO1 expression analysis\",\n      \"pmids\": [\"40721014\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct NRF2 binding to GLO1 promoter not shown\", \"Whether the circuit operates in non-TXNIP-deficient contexts unknown\", \"Single patient-derived cell system\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"GLO1 was shown to promote breast cancer lymph node metastasis by stabilizing GSS against proteasomal degradation, thereby maintaining GSH levels and redox balance and supporting lymphatic angiogenesis.\",\n      \"evidence\": \"Single-cell RNA-seq, multi-omics, GSS proteasomal degradation assay, GSH/ROS measurement, in vivo metastasis models\",\n      \"pmids\": [\"40492378\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical interaction between GLO1 and GSS not demonstrated\", \"E3 ligase targeting GSS not identified\", \"Whether MG itself or a GLO1 protein interaction stabilizes GSS unclear\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"GLO1 enrichment in glioma stem cells and its requirement for GSC viability via Sox2-dependent transcriptional programs established GLO1 as a targetable dependency in glioblastoma stemness maintenance.\",\n      \"evidence\": \"Single-cell transcriptomics, genetic knockdown/overexpression, pharmacological inhibition, PDX and IUE-GBM mouse models\",\n      \"pmids\": [\"42011505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MG directly modifies Sox2 or acts upstream not resolved\", \"Resistance mechanisms to GLO1 inhibition in GSCs not explored\", \"Biomarker for patient selection not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the E3 ligase(s) mediating itaconate-triggered GLO1 degradation, the structural basis by which K157 crotonylation inhibits catalysis, whether GLO1 nuclear translocation serves a distinct non-enzymatic function, and the direct molecular target of MG in neurons that modulates anxiety behavior.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"E3 ligase for itaconate-driven GLO1 degradation unidentified\", \"Structural model of K157-crotonylated GLO1 lacking\", \"Nuclear function of GLO1 undefined\", \"Neuronal MG receptor/target not molecularly identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016853\", \"supporting_discovery_ids\": [0, 2, 14]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 7, 14]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 7, 12, 14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 11, 22]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [8, 13, 14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"YBX1\",\n      \"GSS\",\n      \"SIRT2\",\n      \"HDAC1\",\n      \"HDAC3\",\n      \"MMSET\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}